Drug Database
Back to search

Poland· PL-100525910

Ogsiveo

A other antineoplastic agents product containing nirogacestatum, registered in Poland by SpringWorks Therapeutics Ireland Limited. The same ATC class is registered in 5 of our 19 countries.

ATC L01XX

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedOgsiveoATCL01XXREGISTER NO.PL-100525910PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nirogacestatumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nirogacestatum is registered in 5 of 19 countries.

Countries holding a registration under ATC L01XX (other antineoplastic agents), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose
Search nirogacestatum products by name

Nirogacestatum · ATC L01XX

5 / 19 countries

  • Denmark
  • Finlandprice
  • Ireland
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Nirogacestatum
Manufacturer
SpringWorks Therapeutics Ireland Limited
Country
Poland (PL)
ATC code
L01XX
ATC class
Other antineoplastic agents
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    04150197598227

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Nirogacestatum in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nirogacestatum products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ogsiveo
  • Liechtenstein · Ogsiveo
  • Norway · Ogsiveo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d6975ff1-755d-4394-b1f2-b7fbbc9452fa
GET /v1/drugs/d6975ff1-755d-4394-b1f2-b7fbbc9452fa?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "150 mg",
  "packaging": "Rp ¦ EU/1/25/1932/004 ¦ 163964\n56 tabl.\n¦ UR/Z/4b/102/26 - 04150197598227 ¦ UR/Z/4b/182/26 - 04150197598227 ¦ UR/Z/4b/246/26 - 04150197598227",
  "substance": "Nirogacestatum 150 mg",
  "common_name": "Nirogacestatum",
  "pl_product_id": "100525910",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about nirogacestatum.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console